The Radiochemistry Facility is a shared resource that provides Cancer Center investigators with expertise and facilities for the radiolabeling and quality control of molecules of potential interest for molecular imaging in animal models of human cancer as well as cancer radio-diagnosis and targeted radiotherapy. This is a new facility that has evolved from the Radiolabeling Facility to meet the emerging needs within the Cancer Center for PET radiochemistry to provide probes for evaluating tumor biochemistry and receptor biology, monitoring treatment response, expediting the development of novel therapies and personalizing patient treatment protocols. Although the primary function of the past facility - labeling antibodies for research purposes and clinical trials - will still be performed, the major function of the Radiochemistry Facility will be to provide Duke Comprehensive Cancer Center investigators with the most essential positron emitting radiotracers needed for basic and clinical research. Functions of the facility include consultation with investigators to determine optimum radionuclide, targeting vector and radioligand, radiosynthesis, scale up, and quality control of the labeled product. Finally, the Director is available to work with investigators in the preparation of an Investigational New Drug or Radioactive Drug Research Committee Application to permit patient studies with radiolabeled molecules.
Radiolabeled molecules are essential components of molecular imaging and the targeted radiotherapy of cancer;however, highly specialized radiochemistry equipment and expertise are required for their radios-ynthesis, particularly at the levels needed for clinical studies and many research applications. The radiochemistry facility will perform an important core function by providing radiolabeled molecules to cancer center investigators in a cost effective manner.
|Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131|
|Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790|
|Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408|
|Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224|
|Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031|
|Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675|
|Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312|
|Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462|
|Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784|
|Dai, Ziwei; Mentch, Samantha J; Gao, Xia et al. (2018) Methionine metabolism influences genomic architecture and gene expression through H3K4me3 peak width. Nat Commun 9:1955|
Showing the most recent 10 out of 513 publications